Skip to content
Nonprofiteer
← USONA INSTITUTE INC

Form 990 for tax year 2024

Filed by USONA INSTITUTE INC.

Totals

Total revenue
$7,949,536
Total expenses
$33,737,459
Contributions and grants received
$5,020,285
Grants paid
$167,150
Program service revenue
$211,597
Investment income
$288,752
Other revenue
$2,428,902
Total assets, end of year
$148,230,819
Total liabilities, end of year
$102,614,654
Net assets or fund balances, end of year
$45,616,165
Program services expenses (Part IX)
$31,492,542
Management and general expenses
$2,244,917
Fundraising expenses
$0
Program service expenses (Part III)
$31,492,542

Program services were 93.3% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1f · All other contributions, gifts and grants

    $5,020,285

  • 2a · Program service revenue: SERVICE REVENUE

    total $211,597 · related or exempt $211,597

  • 3 · Investment income

    total $282,146 · excluded $282,146

  • 6a · Gross rents

    real property $49,765

  • 6b · Less rental expenses

    real property $0

  • 6c · Rental income or loss

    real property $49,765

  • 6d · Net rental income or loss

    total $49,765 · excluded $49,765

  • 7a · Gross sales of assets other than inventory

    securities $25,000,000 · other assets $6,606

  • 7b · Less cost or other basis and sales expenses

    securities $25,000,000 · other assets $0

  • 7c · Gain or loss

    securities $0 · other assets $6,606

  • 7d · Net gain or loss

    total $6,606 · excluded $6,606

  • 10a · Gross sales of inventory

    $250,867

  • 10b · Cost of goods sold

    $70,849

  • 10c · Net income from sales of inventory

    total $180,018 · related or exempt $180,018

  • 11a · Other revenue: GREEN ENERGY CREDIT

    total $2,105,619 · excluded $2,105,619

  • 11b · Other revenue: MATERIAL SUPPLY PROGRAM PROCESSIN

    total $93,500 · related or exempt $93,500

  • 11e · Other revenue, total

    $2,199,119

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $24,150 · program services $24,150

  • 2 · Grants to domestic individuals

    total $66,500 · program services $66,500

  • 3 · Grants to foreign organizations and individuals

    total $76,500 · program services $76,500

  • 5 · Compensation of officers, directors and key employees

    total $595,411 · program services $535,869 · management and general $59,542

  • 7 · Other salaries and wages

    total $4,684,036 · program services $3,826,614 · management and general $857,422

  • 8 · Pension plan contributions

    total $351,694 · program services $290,137 · management and general $61,557

  • 9 · Other employee benefits

    total $674,266 · program services $557,787 · management and general $116,479

  • 10 · Payroll taxes

    total $1,344 · program services $1,344

  • 11b · Fees: legal

    total $46,732 · management and general $46,732

  • 11c · Fees: accounting

    total $82,751 · management and general $82,751

  • 11g · Fees: other

    total $17,606,900 · program services $17,555,899 · management and general $51,001

  • 12 · Advertising and promotion

    total $81,864 · program services $81,864

  • 13 · Office expenses

    total $209,760 · program services $95,130 · management and general $114,630

  • 14 · Information technology

    total $26,646 · program services $13,323 · management and general $13,323

  • 16 · Occupancy

    total $254,036 · program services $244,432 · management and general $9,604

  • 17 · Travel

    total $272,414 · program services $136,207 · management and general $136,207

  • 19 · Conferences, conventions and meetings

    total $84,646 · program services $84,646

  • 20 · Interest

    total $1,558,223 · program services $1,480,312 · management and general $77,911

  • 22 · Depreciation, depletion and amortization

    total $2,858,669 · program services $2,681,490 · management and general $177,179

  • 23 · Insurance

    total $195,958 · program services $104,801 · management and general $91,157

  • 24a · Other expenses: INVENTORY EXPENSES

    total $3,369,098 · program services $3,369,098

  • 24b · Other expenses: REPAIRS AND MAINTENANCE

    total $152,464 · program services $144,841 · management and general $7,623

  • 24c · Other expenses: DUES AND SUBSCRIPTIONS

    total $95,225 · program services $38,807 · management and general $56,418

  • 24d · Other expenses: LAB EQUIPMENT SUPPLIES

    total $70,731 · program services $70,731

  • 24e · All other expenses

    total $297,441 · program services $12,060 · management and general $285,381

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $8,028,586 · end of year $4,173,319

  • 4 · Accounts receivable

    beginning of year $181,352 · end of year $223,320

  • 8 · Inventories for sale or use

    beginning of year $5,492,708 · end of year $7,456,369

  • 9 · Prepaid expenses and deferred charges

    beginning of year $2,022,867 · end of year $1,830,081

  • 10a · Land, buildings and equipment: cost or other basis

    $82,091,853

  • 10b · Land, buildings and equipment: accumulated depreciation

    $4,066,998

  • 10c · Land, buildings and equipment, net

    beginning of year $79,428,956 · end of year $78,024,855

  • 12 · Investments: other securities

    beginning of year $31,000,000 · end of year $6,000,000

  • 13 · Investments: program-related

    beginning of year $16,879 · end of year $22,417

  • 15 · Other assets

    beginning of year $54,077,156 · end of year $50,500,458

  • 17 · Accounts payable and accrued expenses

    beginning of year $7,479,972 · end of year $4,460,038

  • 18 · Grants payable

    beginning of year $99,047 · end of year $0

  • 19 · Deferred revenue

    beginning of year $6,290 · end of year $7,500

  • 23 · Secured mortgages and notes payable

    beginning of year $47,681,587 · end of year $46,460,866

  • 25 · Other liabilities

    beginning of year $53,861,525 · end of year $51,686,250

  • 27 · Net assets without donor restrictions

    beginning of year $68,032,246 · end of year $44,231,335

  • 28 · Net assets with donor restrictions

    beginning of year $3,087,837 · end of year $1,384,830

Mission and programs · 2024

Mission

USONA INSTITUTE HAS BEEN ORGANIZED TO OPERATE EXCLUSIVELY FOR CHARITABLE, SCIENTIFIC, AND EDUCATIONAL PURPOSES, INCLUDING, BUT NOT LIMITED TO, CONDUCTING AND SUPPORTING MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCE RESEARCH AND EDUCATION ON MEDICINES AND PRACTICES TO RELIEVE MENTAL AND PHYSICAL SUFFERING AND TO IMPROVE THE QUALITY OF LIFE AND MANAGEMENT OF HEALTH CARE THROUGH THE APPLICATION OF TREATMENTS USING SAFE AND EFFECTIVE PRODUCTS, INCLUDING THOSE DERIVED FROM PLANTS AND RELATED MATERIALS. IN ADDITION, THE INSTITUTE QUALIFIES AS A "MEDICAL RESEARCH ORGANIZATION" UNDER SECTION 170(B)(1)(A)(III), AS IT HAS A PRINCIPAL PURPOSE OF CONDUCTING MEDICAL RESEARCH AND WILL BE PRIMARILY ENGAGED IN MEDICAL RESEARCH IN CONJUNCTION WITH UNIVERSITY OF WISCONSIN HOSPITALS AND CLINICS.

Activities or mission (Part I)

USONA INSTITUTE IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO SUPPORTING AND CONDUCTING BASIC, PRE-CLINICAL AND CLINICAL RESEARCH TO FURTHER THE SCIENTIFIC UNDERSTANDING AND THERAPEUTIC APPLICATION OF CONSCIOUSNESS-EXPANDING MEDICINES.OUR FOCUS IS THE TREATMENT OF SOCIETY'S MOST CHALLENGING MENTAL HEALTH CONDITIONS FOR WHICH EXISTING TREATMENTS FALL SHORT.

  • PSIL301 STUDYUSONA INSTITUTE IS CONDUCTING A PHASE 3 CLINICAL TRIAL, "A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PSILOCYBIN IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD)," ALSO KNOWN AS THE UASPIRE TRIAL. THIS RESEARCH SEEKS TO INVESTIGATE THE POTENTIAL BENEFITS AND SAFETY OF PSILOCYBIN AS A TREATMENT OPTION FOR INDIVIDUALS WITH MAJOR DEPRESSIVE DISORDER AS QUICKLY AND SAFELY AS POSSIBLE.2024 ACCOMPLISHMENTSTHE UASPIRE PSIL301 PHASE 3 TRIAL ADDED NEW SITES ACROSS NORTH AMERICA, INCLUDING VETERANS AFFAIRS (VA) SITES, TO ENHANCE PATIENT DIVERSITY AND STRENGTHEN DATA RELIABILITY TO SUPPORT REGULATORY APPROVAL AND ENSURE BROAD APPLICABILITY OF FINDINGS. ONGOING COLLABORATION WITH THE FDA UNDER OUR BREAKTHROUGH THERAPY DESIGNATION, IN PREPARING FOR NDA SUBMISSION UPON COMPLETION OF PHASE 3. THE CMC TEAM SCALED UP API PRODUCTION, MAINTAINED STRINGENT QUALITY CONTROLS, AND SECURED NEW MANUFACTURING PARTNERSHIPS TO SUPPORT HIGH-QUALITY PSILOCYBIN PRODUCTION IN ANTICIPATION OF MARKET ACCESS. FACILITATOR TRAINING EXPANDED ACROSS ALL PHASE 3 SITES TO ENSURE CONSISTENT IN-PATIENT CARE. EARLY MARKET ACCESS EFFORTS INCLUDED PARTNERSHIPS WITH DIVERSE STAKEHOLDERS FOCUSING ON UNDERSERVED POPULATIONS, ENHANCING INFRASTRUCTURE AND SUPPLY CHAIN RESILIENCE FOR EQUITABLE ACCESS.GUIDED BY A DIVERSITY STEERING COMMITTEE, THE PLAN INCORPORATED INSIGHTS FROM COMMUNITY OUTREACH AND DIVERSITY EXPERTS TO RECRUIT UNDERREPRESENTED POPULATIONS AND FOSTER INCLUSION IN THE PSIL301 PHASE 3 STUDY.

    Expenses $27,713,437

  • 5-MEO-DMT PHASE 2 STUDYUSONA INSTITUTE IS CONDUCTING A TWO-PART (PHASE 2A/2B) CLINICAL TRIAL (MEO201) TO EVALUATE THE EFFICACY AND SAFETY OF 5-MEO-DMT FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER (PTSD) IN ADULTS. THE GOALS IN PART A (PHASE 2A) ARE TO OBTAIN SAFETY DATA AND EFFECT SIZE ESTIMATES IN A PTSD PATIENT POPULATION AND GAIN KNOWLEDGE AND EXPERIENCE TO OPTIMIZE PART B (PHASE 2B) DESIGN. THE GOAL IN PART B (PHASE 2B) IS TO EVALUATE THE SAFETY AND EFFICACY OF THE 5-MEO-DMT REGIMEN SELECTED FROM PART A. 2024 ACCOMPLISHMENTSREFINED PHASE 2 PROTOCOLS USING PHASE 1 DATA, OPTIMIZING SAFETY AND DOSING TO IMPROVE PATIENT OUTCOMES. INITIATED SITE SELECTION AND DEVELOPING FACILITATOR TRAINING PROGRAM TO ENSURE HIGH STANDARDS AND TRIAL QUALITY. PLANNING FOR A 2025 TRIAL LAUNCH TO EVALUATE 5-MEO-DMT'S EFFICACY WITH MULTIPLE SITES IN THE U.S. AND CANADA.

    Expenses $3,149,254

  • EVENTS & PROGRAMSUSONA'S EDUCATION PROGRAMS ARE INTENTIONALLY DESIGNED TO PROVIDE IMMERSIVE AND INTERACTIVE LEARNING EXPERIENCES. THESE PROGRAMS FOCUS ON PREPARING CLINICAL, SCIENTIFIC, AND ACADEMIC LEADERS WITH THE CRITICAL KNOWLEDGE NEEDED TO ADVANCE PSYCHEDELIC THERAPY IN CLINICAL RESEARCH AND PREPARATION FOR FUTURE DELIVERY OF CARE, UPON APPROVAL. THROUGH A CAREFULLY TAILORED CURRICULUM, DIVERSE FACULTY, EXPERIENTIALS, AND GUEST SPEAKERS, PARTICIPANTS GAIN THE EXPERTISE AND FOUNDATIONAL KNOWLEDGE REQUIRED TO PAVE THE WAY FOR BEST PRACTICES IN FUTURE CARE DELIVERY MODELS. 2024 ACCOMPLISHMENTSHOSTED OVER 300 ATTENDEES AT TEN EVENTS AT THE USONA CAMPUS IN 2024, BROADENING USONA'S IMPACT IN PSYCHEDELIC THERAPY EDUCATION. EXPANDED THE PROGRAM OFFERINGS AND CURRICULUM WITH IMMERSIVE PROGRAMS DESIGNED TO PREPARE SCIENTIFIC, CLINICAL, AND ACADEMIC LEADERS. AWARDED FULL AND PARTIAL SCHOLARSHIPS FOR PARTICIPATION IN USONA'S IMMERSIVE EDUCATION PROGRAMS, EXPANDING ACCESS AND DIVERSITY OF PARTICIPANTS. LAUNCHED ENHANCED FACILITATOR TRAINING TO SUPPORT THE PHASE 3 PSILOCYBIN CLINICAL TRIAL. STRENGTHENED PARTNERSHIPS WITH RESEARCH AND ACADEMIC INSTITUTIONS TO PREPARE PRACTITIONERS AND FACULTY FOR FUTURE CARE DELIVERY.

    Expenses $629,851 · Grants $167,150 · Revenue $485,115

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • William A Linton

    PRESIDENT

    Total calculated
    $0
    Hours/week
    10 + 1 related

  • Mathew Saur

    SECRETARY

    Total calculated
    $0
    Hours/week
    1 + 1 related

  • Poncho Meisenheimer

    BOARD MEMBER/DIRECTOR OF CHEMISTRY

    Total calculated
    $24,000
    From this org
    $24,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    5 + 1 related

  • Rachelle Sampson

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 1 related

  • Richard Langer

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    5 + 1 related

  • John Leblanc

    TREASURER

    Total calculated
    $340,486
    From this org
    $306,326
    From related orgs
    $0
    Other
    $34,160
    Hours/week
    24 + 1 related

    Schedule J breakdown matched by us

    Base
    $300,992
    Bonus
    $0
    Other
    $5,334
    Deferred
    $13,005
    Nontaxable benefits
    $21,155
    Filer's total
    $340,486

  • David Judson

    DIRECTOR QUALITY ASSURANCE

    Total calculated
    $230,963
    From this org
    $221,589
    From related orgs
    $0
    Other
    $9,374
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $212,937
    Bonus
    $0
    Other
    $8,652
    Deferred
    $9,374
    Nontaxable benefits
    $0
    Filer's total
    $230,963

  • Mike Davis

    CHIEF MEDICAL OFFICER

    Total calculated
    $496,806
    From this org
    $447,398
    From related orgs
    $0
    Other
    $49,408
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $446,768
    Bonus
    $0
    Other
    $630
    Deferred
    $13,800
    Nontaxable benefits
    $35,608
    Filer's total
    $496,806

  • Theraysa Gapasin

    SENIOR CLINICAL PROGRAM LEAD

    Total calculated
    $254,787
    From this org
    $222,002
    From related orgs
    $0
    Other
    $32,785
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $221,036
    Bonus
    $0
    Other
    $966
    Deferred
    $10,324
    Nontaxable benefits
    $22,461
    Filer's total
    $254,787

  • Katarzyna Warchol

    CLINICAL OPERATIONS MANAGER

    Total calculated
    $242,759
    From this org
    $211,533
    From related orgs
    $0
    Other
    $31,226
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $211,155
    Bonus
    $0
    Other
    $378
    Deferred
    $8,765
    Nontaxable benefits
    $22,461
    Filer's total
    $242,759

  • Robert Ezzell

    DIRECTOR RA PHARMACEUTICAL PRODUCTS

    Total calculated
    $291,917
    From this org
    $259,071
    From related orgs
    $0
    Other
    $32,846
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $250,418
    Bonus
    $0
    Other
    $8,653
    Deferred
    $10,385
    Nontaxable benefits
    $22,461
    Filer's total
    $291,917

  • Tura Patterson

    DIRECTO OF STRATEGIC PARTNERSHIPS

    Total calculated
    $289,954
    From this org
    $262,041
    From related orgs
    $0
    Other
    $27,913
    Hours/week
    36

    Schedule J breakdown matched by us

    Base
    $261,172
    Bonus
    $0
    Other
    $869
    Deferred
    $11,456
    Nontaxable benefits
    $16,457
    Filer's total
    $289,954

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

None.

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

  • CINQUE TERRE LLC

    REAL ESTATE HOLDINGS · WI · income $0 · assets $76,197,057

    Directly controlled by USONA INSTITUTE INC

  • PORTA SOPHIA LLC

    SEARCH TOOL FOR INNOVATORS AND PATENT REVIEWERS IN THE FIELD OF PSYCHEDELICS · WI · income $152,642 · assets $147,899

    Directly controlled by USONA INSTITUTE INC

Related corporations and trusts

Part IV: related organizations taxable as a corporation or trust.

  • USONA INSTITUTE EUROPA GMBH

    C · SCIENCE RESEARCH · GM · 100% owned · share of income $11,687 · share of assets $5,604 · controlled entity

    Directly controlled by USONA INSTITUTE INC

Provenance

Return type
form_990
Tax year
2024
Filed
2 May 2025
IRS schema version
2024v5.1
Source object
202531269349301298

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.